Cargando…

Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer

INTRODUCTION: Antibiotic use is a risk factor for Clostridioides difficile infection (CDI). Few studies have correlated use of prior antibiotic classes with CDI, microbiome composition, and disease severity in patients with cancer. We hypothesized that previous antibiotic exposure and fecal microbio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Francisco, Denise Marie A., Zhang, Liangliang, Jiang, Ying, Olvera, Adilene, Adachi, Javier, Guevara, Eduardo Yepez, Aitken, Samuel L., Garey, Kevin W., Peterson, Christine B., Do, Kim-Anh, Dillon, Ryan, Obi, Engels N., Jenq, Robert, Okhuysen, Pablo C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868205/ https://www.ncbi.nlm.nih.gov/pubmed/36443547 http://dx.doi.org/10.1007/s40121-022-00722-9

Ejemplares similares

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

2380. Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile
por: A. Francisco, Denise Marie, et al.
Publicado: (2019)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea
por: Guevara, Eduardo Yepez, et al.
Publicado: (2017)

Risk Factors and Clinical Outcomes of Cancer Patients with Clostridium difficile Associated Diarrhea Co-infected with a Second Enteropathogen
por: Yalamanchili, Harika, et al.
Publicado: (2017)

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
por: Hengel, Richard L., et al.
Publicado: (2022)

Line of Service-Specific Performance and Antibiotic Prescribing Habits Following Introduction of a Two-Step Diagnostic Approach Using NAAT Followed by Enzyme Immunoassay in Cancer Patients with Suspected Clostridium difficile Infection
por: Chao, Andrew, et al.
Publicado: (2017)

1100. Characterization of Enteropathogenic Escherichia coli (EPEC) in Cancer Patients With Diarrhea
por: Okhuysen, Pablo, et al.
Publicado: (2018)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile—A Retrospective Observational Study
por: Deshpande, Abhishek, et al.
Publicado: (2022)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

757. Evaluating Use of the New ICD-10 Codes for Clostridioides difficile Infection in the Premier U.S. Hospital Discharge Database
por: Deshpande, Abhishek, et al.
Publicado: (2021)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

700. Risk Factors and Molecular Epidemiology of Acute and Chronic Norovirus Infection at a Large Tertiary Care Cancer Center
por: Kondapi, Divya S, et al.
Publicado: (2021)

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients
por: Ali, Hiba, et al.
Publicado: (2021)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022)

674. Host and Pathogen Risk Factors for Fulminant Clostridioides difficile Infection
por: Chua, Hubert C, et al.
Publicado: (2023)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

18. Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings
por: Jo, Jinhee, et al.
Publicado: (2021)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

1098. Norovirus Infection in Cancer Patients Undergoing Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T)
por: Kondapi, Divya S, et al.
Publicado: (2020)

2402. Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection
por: Alonso, Carolyn D, et al.
Publicado: (2021)

678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
por: Dubberke, Erik R, et al.
Publicado: (2023)

Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study
por: Bouza, Emilio, et al.
Publicado: (2021)

2388. High-risk antibiotics associated with Clostridioides difficile infection: a national, multicenter analysis
por: Young, Eric H, et al.
Publicado: (2019)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

802. Proton Pump Inhibitors Increase Clostridioides difficile Disease Severity Controlling for Infecting Strains
por: Fallatah, Saad, et al.
Publicado: (2020)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mavpsjol1e9ego2rgqg1siiemf